Powder: -20°C for 3 years | In solvent: -80°C for 1 year
HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 (IC50s: 34 nM and 33 nM). HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 72.00 | |
5 mg | In stock | $ 155.00 | |
10 mg | In stock | $ 239.00 | |
25 mg | In stock | $ 487.00 | |
50 mg | In stock | $ 696.00 | |
100 mg | In stock | $ 987.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 197.00 |
Description | HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 (IC50s: 34 nM and 33 nM). HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation. |
Targets&IC50 | EGFR:34 nM, ErbB2:33 nM |
In vitro | HKI-357 also is effective in suppressing EGFR autophosphorylation (measured at residue Y1068), and AKT and MAPK phosphorylation in parental NCI-H1650 cells harboring the delE746-A750 EGFR mutation.HKI-357 (0.01-10 μM) is effective in suppressing ligand-induced EGFR autophosphorylation and its downstream signaling, as determined by AKT and MAPK phosphorylation in NCI-H1975 cells. |
Molecular Weight | 574.05 |
Formula | C31H29ClFN5O3 |
CAS No. | 848133-17-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 11 mg/mL (19.16 mM), Sonification is recommended
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
HKI-357 848133-17-5 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR HKI357 Inhibitor HKI 357 ErbB-1 HER1 inhibit NSCLCs Epidermal growth factor receptor ERBB2 inhibitor